10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.5 USD | -0.46% | -1.37% | -65.15% |
06-25 | Guggenheim Downgrades 10x Genomics to Neutral From Buy | MT |
06-03 | Jefferies Initiates 10x Genomics at Hold Rating With $24 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.15% | 2.33B | |
-9.64% | 11.57B | |
-12.79% | 7.37B | |
+26.65% | 5.44B | |
-17.87% | 3.74B | |
+7.41% | 2.58B | |
+28.63% | 2.23B | |
-11.56% | 2.21B | |
-14.32% | 1.67B | |
-9.41% | 1.4B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024